Related Experiment Videos
[Current developments in systemic therapy of breast carcinoma].
1Institut für Medizinische Onkologie der Universitätsklinik Bern, Inselspital.
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis
|March 12, 1991
Summary
New treatments for metastatic breast cancer include hormone therapies like LH-RH antagonists and improved antiestrogens/aromatase inhibitors, alongside chemotherapy strategies focused on quality of life and risk adaptation, not just remission rates.
Area of Science:
- Oncology
- Endocrinology
Context:
- Metastatic breast cancer treatment involves complex hormonal and chemotherapeutic approaches.
- Current research focuses on optimizing therapies for premenopausal and postmenopausal women.
Purpose:
- To review recent advancements in hormone and chemotherapy for metastasizing breast cancer.
- To discuss the evolving goals of treatment, emphasizing quality of life and risk-adapted strategies.
Summary:
- Hormone therapy innovations include LH-RH antagonists replacing ovariectomy and new antiestrogens/aromatase inhibitors with improved side effect profiles.
- Chemotherapy research explores high-dose regimens with bone marrow transplantation, though results are currently disappointing.
- The focus shifts from high remission rates to palliative care and symptom management, tailored to individual risk profiles.
- Newer chemotherapeutic agents are derivatives of existing ones, aiming for reduced side effects with equal efficacy.
Impact:
- These developments offer potential for improved efficacy and reduced side effects in breast cancer treatment, albeit at a higher cost.
- The findings underscore the importance of personalized treatment strategies based on prognostic indicators for metastatic breast cancer.
- The shift towards quality of life highlights a more patient-centered approach in managing advanced-stage disease.